|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer.
|
1346099 |
1992 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study was undertaken to examine whether amplification, rearrangement, or overexpression of c-erbB-2 and other protooncogenes was frequently observed in epithelial ovarian cancers. c-erbB-2 was expressed in 87% of 22 ovarian cancers analyzed, but expression was significantly increased in only one of the 22 tumor specimens.
|
1679963 |
1991 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the human neu gene was shown to be amplified/overexpressed in a large portion of human breast and ovarian cancer, no reports indicate that the human neu gene is activated by a point mutation in human tumor.
|
2206283 |
1990 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
c-erbB-2 oncogene expression in ovarian cancer.
|
2266460 |
1990 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
|
2470152 |
1989 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that amplification of the c-erb B-2/neu gene may play a role in the pathogenesis of ovarian carcinoma.
|
2569708 |
1989 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with advanced breast or ovarian cancer that overexpressed HER-2/neu were eligible for treatment.
|
7545221 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
|
7557620 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, neither c-erbB2 gene amplification nor c-erbB2 protein over-expression appears to be a significant prognostic marker in patients with ovarian carcinoma.
|
7615357 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis.
|
7685420 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, few reports suggest that c-erbB-2/neu, which is a prognostic marker in breast cancer, epidermal growth factor receptor (EGFR), which is overexpressed in a variety of neoplasms, and fibroblast growth factor-3 (FGF-3/INT-2), which has been found to be amplified in breast and ovarian cancer, could be implicated in the development of endometrial adenocarcinoma.
|
7697605 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER-2/neu has been demonstrated in human ovarian cancer and correlated with poor prognosis.
|
7761095 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that amplification of the C-erbB-2 gene may play a role in the pathogenesis of ovarian carcinoma; it is frequently observed in advanced ovarian cancer and is associated with poor prognosis for these patients.
|
7805442 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The finding that erbB2 product in ovarian cancer is mostly localised in cytoplasm and not in the membrane as in breast cancer and that it has a lower molecular weight than the p185 in breast cancer suggest that this oncogene plays a different biological role in these two neoplasms.
|
7904177 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The authors analyzed the expression of HER-2/neu on frozen tumor specimens from 40 patients with early epithelial ovarian cancer using the indirect immunoperoxidase technique with monoclonal antibodies that detect epitopes on the extracellular domain of the HER-2/neu protein.
|
7906607 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
|
7906608 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucocorticoid regulation of HER-2/neu expression was investigated using the SK-OV-3 human epithelial ovarian cancer cell line in which the HER-2/neu gene is amplified five- to eightfold.
|
7909787 |
1994 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu expression does not appear to be an important prognostic factor in patients with advanced epithelial ovarian cancer.
|
8093588 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously found that the ovarian carcinoma cell line SK-OV-3 overexpresses c-erbB-2/neu mRNA.
|
8094034 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas.
|
8096121 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
No genomic rearrangements by Southern blotting were seen in the brcAI candidate gene estradiol 17 beta dehydrogenase 2 (17hsd2), or in erbB2, prohibition (phb) and nmeI (previously nm23-HI).
|
8098014 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer.
|
8522248 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The amplification rate of C-myc, C-N-ras, C-Ki-ras and C-erbB-2 in ovarian carcinoma were 50%, 44%, 31% and 25% respectively.
|
8585978 |
1995 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
|
8725881 |
1996 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
|
8818660 |
1996 |